UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The trend of prescribing semaglutide to treat cardiovascular disease is expected to continue to grow. At the American College ...

The largest study to date suggests that patients at high risk for heart attacks and strokes should begin immediate treatment with a combination of a statin and ezetimibe. The largest study to date exa ...

A retrospective cohort study revealed that nicotinamide exposure among adults did not increase the risk for major adverse cardiovascular events.

Germany: A recent systematic review and meta-analysis published in Nature Medicine highlighted the benefits of intravenous ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

Early introduction of atorvastatin in patients with hypertension demonstrates sustained cardiovascular benefits, a 20-year ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® ...